A10BK01 - Suchergebnisse

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

forxiga 5 mg filmtabletten

astrazeneca ag - dapagliflozinum - filmtabletten - dapagliflozinum 5 mg zu dapagliflozinum propandiolum monohydricum 6.15 mg, cellulosum microcristallinum, lactosum 25 mg, crospovidonum, silica colloidalis hydrica, magnesium stearas, Überzug: poly(alkohol vinylicus), e 171, macrogolum 3350, talkum, e 172 (gelb), für compresso dunst. - diabetes typ-2, herzinsuffizienz, chronische nierenerkrankung - synthetika

Schweiz - Deutsch - Swissmedic (Swiss Agency for Therapeutic Products)

forxiga 10 mg filmtabletten

astrazeneca ag - dapagliflozinum - filmtabletten - dapagliflozinum 10 mg zu dapagliflozinum propandiolum monohydricum 12.30 mg, cellulosum microcristallinum, lactosum 50 mg, crospovidonum, silica colloidalis anhydrica, magnesium stearas, Überzug: poly(alkohol vinylicus), e 171, macrogolum 3350, talkum, e 172 (gelb), für compresso dunst. - diabetes typ-2, herzinsuffizienz, chronische nierenerkrankung - synthetika

Europäische Union - Deutsch - EMA (European Medicines Agency)

edistride

astrazeneca ab - dapagliflozin-propandiol-monohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogen bei diabetes verwendet - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. zusätzlich zu anderen arzneimitteln für die behandlung von typ-2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 und 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Europäische Union - Deutsch - EMA (European Medicines Agency)

forxiga

astrazeneca ab - dapagliflozin-propandiol-monohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogen bei diabetes verwendet - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. zusätzlich zu anderen arzneimitteln für die behandlung von typ-2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 und 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Europäische Union - Deutsch - EMA (European Medicines Agency)

dapagliflozin viatris

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogen bei diabetes verwendet - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 und 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.